PR Newswire Clinical TrialsOriginal article
Lighthouse Pharmaceuticals Reports New Evidence that Gingipain Inhibition Benefits Neuropsychiatric Symptoms and Reduces Caregiver Distress in P. gingivalis-Positive Alzheimer's Disease at AAIC 2026
Data ReadoutpositiveatuzaginstatPositive
AI Analysis
Summary
Lighthouse Pharmaceuticals announced new Phase 2/3 GAIN trial data showing atuzaginstat, a gingipain inhibitor, provided benefits for neuropsychiatric symptoms and reduced caregiver distress in P. gingivalis-positive Alzheimer's Disease patients.
Clinical Trial Data
Phase
Phase 2/3
Outcome Details
Phase 2/3 GAIN trial demonstrated benefits in neuropsychiatric symptoms and reduced caregiver distress in P. gingivalis-positive Alzheimer's Disease patients
Importance:6/10
Sentiment:
0.70
Alzheimer's Diseasegingipain inhibitorPorphyromonas gingivalisneuropsychiatric symptomsPhase 2/3GAIN trialAAIC 2026
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 13, 2026 8:00 AM